Clinical Trials Logo

Lupus Erythematosus, Systemic clinical trials

View clinical trials related to Lupus Erythematosus, Systemic.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06029335 Active, not recruiting - Healthy Clinical Trials

Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune Diseases

Start date: September 1, 2020
Phase:
Study type: Observational

Objectives: Systemic autoimmune diseases are chronic diseases characterized by chronic inflammation, vasculopathy, and autoimmune phenomena. Several organ involvements are typical, including the central nervous system. Formerly published investigations emphasize a mild cognitive impairment affecting attention, memory, and complicated solution tasks. However, these symptoms significantly impact patients' routines and quality of life. The study examined the associations between cognitive impairment and clinical parameters regarding systemic autoimmune diseases. Methods: General clinical data, some serum biomarkers including CCl-18, YKL-40, COMP, VEGF, Galectin-3, and Pentraxin as well as results of functional, quality of life, and neuropsychological measures, the Mini-Mental State Examination (MMSE), the Digit Span Forward-Backward, the Trail making A, B and the Digit Symbol tests all were administered.

NCT ID: NCT05478018 Active, not recruiting - Clinical trials for Systemic Lupus Erythematosus

Type 1 Interferon Induced Changes to Exercise Adaptations in Systemic Lupus Erythematosus Patients

LUPEX
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Investigating the physiological effects of the interferons type 1 and 2 (IFNs), and the cytokines Interleukin 6 (IL-6) and tumor necrosis factor (TNF) on the adaptive changes to exercise in patients with systemic lupus erythematosus (SLE). The investigators hypothesize that the pathogenic blockage of IL-6 signalling that occurs in SLE, will decrease the cardiac and metabolic adaptations to aerobic exercise, and this decrease can be related to the IFN signature. 55 patients was included in a 12-week investigator blinded 1:1 randomised high intensity aerobic exercise intervention study.

NCT ID: NCT05379725 Active, not recruiting - Clinical trials for Lupus Erythematosus, Systemic

Mediterranean vs. High-Fermented-Food Diet Adherence on Inflammation in Lupus

Start date: July 22, 2022
Phase: N/A
Study type: Interventional

This is a 4-month randomized controlled trial to evaluate the feasibility of 'good and very good' adherence to the Mediterranean dietary pattern and to a high-fermented-food diet by individuals with Systemic lupus erythematosus (SLE).

NCT ID: NCT05347992 Active, not recruiting - Clinical trials for Systemic Lupus Erythematosus

ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)

ELEVATE
Start date: May 3, 2022
Phase:
Study type: Observational

To explore the potential for use of DxTerity's AIP IFN-1 test as personalized guided care and monitoring module in patients with Systemic lupus erythematosus(SLE) using consented patient health information

NCT ID: NCT05328557 Active, not recruiting - Clinical trials for Systemic Lupus Erythematosus

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

Start date: November 7, 2021
Phase: Phase 1
Study type: Interventional

The intent of this study is to evaluate the safety and tolerability of single escalating subcutaneous doses of CUG252 in healthy adult subjects.

NCT ID: NCT05289544 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Phone-Based Based Walk With Ease Program for Adults With Arthritis

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to examine the short-term (6-weeks and 6 months) and long-term (1 year) effects of a phone-based version of Walk With Ease intervention.

NCT ID: NCT05162586 Active, not recruiting - Clinical trials for Systemic Lupus Erythematosus

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Start date: March 31, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE; subacute cutaneous lupus erythematosus [SCLE] and/or discoid lupus erythematosus [DLE]) participants in a randomized, double-blind, placebo-controlled, parallel, adaptive and dose-ranging setting. Study Duration: 33 weeks Visit Frequency: every 2 or 4 weeks Enpatoran is not available through an expanded access program.

NCT ID: NCT05155345 Active, not recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

Start date: January 11, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mosunetuzumab in participants with systemic lupus erythematosus (SLE).

NCT ID: NCT05141201 Active, not recruiting - Clinical trials for Lupus Erythematosus, Systemic

SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

Start date: December 21, 2021
Phase:
Study type: Observational

To collect information on and evaluate the long-term safety and effectiveness of Anifrolumab in patients with systemic lupus erythematosus in the real-world post-marketing setting.

NCT ID: NCT05116163 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology

Start date: June 17, 2022
Phase: N/A
Study type: Interventional

The first aim of this study is to test the efficacy of a real-time provider-based individuation intervention to improve the receipt of high-quality rheumatic disease care among Black/African American and lower socioeconomic status (SES) individuals. The second aim is to determine the effect of the individuation intervention on provider-patient communication, adherence, provider trust and care satisfaction.